GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsyGlobeNewsWire • 09/23/20
GW Pharmaceuticals plc (GWPH) CEO Justin Gover Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/15/20
Greenwich Biosciences to Present Data on Safety and Efficacy of Nabiximols in Persons with Multiple Sclerosis-Associated Spasticity at the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020GlobeNewsWire • 09/10/20
Greenwich Biosciences to Share Results of Cannabis Use Survey Conducted with the North American Research Committee on Multiple Sclerosis (NARCOMS) at Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020GlobeNewsWire • 09/10/20
GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of DirectorsGlobeNewsWire • 09/10/20
The Cannabis Industry Needs Hard Data on Medical Marijuana. This Study Could Provide ItThe Motley Fool • 08/09/20